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To the Editor:  Streptococcus 
pneumoniae is a major human patho-
gen. In 2007, Park et al. identiﬁ  ed a 
novel serotype, 6C (1), which emerged 
from serotype 6A. A study of chil-
dren in the Netherlands who had not 
previously received a pneumococcal 
vaccine found low prevalence of this 
newly identiﬁ  ed serotype before the 
heptavalent pneumococcal conjugate 
vaccine Prevnar/Prevenar (PCV7) 
(Wyeth, Taplow, UK) was introduced 
(2). Studies have shown cross-protec-
tion between vaccine serotype 6B and 
vaccine-related serotype 6A. How-
ever, PCV7 elicits no cross-protection 
against serotype 6C.
The potential exists for the emer-
gence of nonvaccine serotypes or novel 
clones. These serotypes and clones may 
be better adapted to colonize the na-
sopharynx, evade the human immune 
response, and cause disease. A recent 
study showed an increase in prevalence 
of serotype 6C pneumococci in chil-
dren and a corresponding decrease in 
serotype 6A after introduction of PCV7 
(3). We studied the underlying genetic 
basis for expansion of serotype 6C. 
Initial data from an ongoing study of 
pneumococcal carriage are presented.
This study was reviewed and ap-
proved by the Southampton and South 
West Hampshire Research Ethics Com-
mittee (B) (reference 06/Q1704/105). 
A total of 697 nasopharyngeal swab 
specimens were collected from unse-
lected (not selected by a method) chil-
dren <4 years of age in the pediatric 
outpatient department of a large teach-
ing hospital in the United Kingdom. 
Samples were obtained during October 
2006–March 2007, during implemen-
tation of PCV7 in the infant immuni-
zation schedule of the United King-
dom. During October 2007–March 
2008, a total of 202 pneumococci were 
isolated. All pneumococci were char-
acterized by serotype and genotype.
In the ﬁ   rst year of this study, 
we identiﬁ   ed 3 (3.1%) serotype 6C 
pneumococci belonging to 3 se-
quence types (STs): ST65, ST1714, 
and ST1692 (online Appendix Figure, 
available from www.cdc.gov/EID/
content/16/1/154-appF.htm). ST1714 
and ST 1692 shared a common clonal 
complex. Only ST 65 was shared be-
tween serotype 6C and serotype 6A. 
In the second year, we identiﬁ  ed 14 
(13.6%) serotype 6C pneumococci 
belonging to 6 STs (online Appen-
dix Figure). Two of these STs, of the 
same ST, were from siblings. Three of 
them (ST1692 [n = 8], ST1714 [n = 
2], and ST395 [n = 1]) were members 
of a common clonal complex with a 
predicted founder of ST395. Each of 
the remaining 3 STs (ST398, ST1862, 
and ST3460) was isolated only once. 
One serotype 6A isolate of ST1692 
was also observed.
No serotype 6C ST65 was ob-
served in the second year. We isolated 
more serotype 6C pneumococci in year 
2 than in year 1 (p<0.01), which was 
explained mostly by a large increase 
in ST1692 (p<0.03) (online Appendix 
Figure). A recent study by Nunes et al. 
reported serotype 6C ST1692 within 
a clonal complex that also included 
ST395 and ST1714 (4), and we identi-
ﬁ  ed the same clonal complex in year 2 
of our study.
Our study showed a large increase 
in ST1692 in serotype 6C pneumo-
cocci during the implementation of 
PCV7 and an increase in serotype 
6C. Depending on the extent of cross-
protection between vaccine-related 
serotypes, introduction of conjugate 
vaccines could induce clearance or 
emergence of vaccine-related sero-
types. This introduction could also 
contribute to their substitution with 
novel or existing serotypes that are 
better adapted to the ecologic niche. 
However, our data may only be rel-
evant to carried pneumococci and not 
reﬂ  ected in pneumococcal disease epi-
demiology. Nevertheless, the increase 
in serotype 6C pneumococci in the 
United Kingdom, which is supported 
by a similar observation in the United 
States (3), highlights the potential for 
emergence of serotypes not included in 
the current study and newly developed 
pneumococcal conjugate vaccines.
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Oseltamivir- and 
Amantadine-
Resistant Inﬂ  uenza 
Virus A (H1N1)
To the Editor: We previously re-
ported detection of double resistance to 
oseltamivir and amantadine of inﬂ  uenza 
virus A (H1N1) in Hong Kong during 
the ﬁ  rst half of 2008 (1). Three different 
strains of A/Hong Kong/2652/2006-
like (clade 2C) viruses that carried 
the S31N mutation in the matrix (M2) 
gene associated with amantadine re-
sistance acquired a neuraminidase 
(NA) gene with CAT→TAT change at 
position 274 through either reassort-
ment with an oseltamivir-resistant A/
Brisbane/59/2007-like (clade 2B) virus 
or spontaneous H274Y mutation in the 
NA gene. A clade 2C strain resistant to 
both oseltamivir and amantadine also 
was detected in Cambodia in 2007 (2).
From July 2008 through Decem-
ber 2008, we continued to monitor 
antiviral susceptibility of all inﬂ  u-
enza A (H1N1) viruses in our labo-
ratory, using previously described 
methods (1). Resistance to oselta-
mivir increased from 16.9% in July 
to 97.8% in December (Table). Se-
quencing of the hemagglutinin (HA) 
gene showed that, beginning in Oc-
tober, A/Brisbane/59/2007-like clade 
2B virus had overtaken A/Hong 
Kong/2652/2006-like clade 2C virus 
to become the predominating circulat-
ing inﬂ  uenza A virus (H1N1) in Hong 
Kong. Of 916 isolates, 6 (0.7%), iso-
lated from July through September 
2008, were resistant to both amanta-
dine and oseltamivir. Genetic analysis 
showed that 5 were similar to those 
we described previously, 4 were A/
Hong Kong/2652/2006-like clade 2C 
viruses with spontaneous H274Y mu-
tation in the NA gene, and 1 was a 
clade 2C virus but acquired a clade 
2B NA gene carrying the H274Y mu-
tation. The sixth double-resistant vi-
rus was an A/Brisbane/59/2007-like 
clade 2B virus with a spontaneous 
S31N mutation in the M2 gene. No 
epidemiologic link was detectable 
between these viruses. From October 
through December 2008, no double-
resistant viruses were detected.
From January through June 2009, 
A/Brisbane/59/2007-like clade 2B vi-
rus continued to be the predominating 
strain. Of the total 1,537 inﬂ  uenza vi-
rus A (H1N1) isolates tested during the 
period, 1,509 (98.2%) were resistant 
to oseltamivir. Of the 1,509 oseltami-
vir-resistant isolates tested from April 
through June 2009, 50 (3.3%) also 
were resistant to amantadine (Table). 
Nucleotide sequencing of the HA, NA, 
and M2 genes was performed on all 50 
oseltamivir- and amantadine-resistant 
viruses. All were A/Brisbane/59/2007-
like clade 2B viruses that had acquired 
an M2 gene carrying the S31N mutation 
by reassortment with an amantadine-
resistant A/Hong Kong/2652/2006-
like clade 2C virus. Nucleotide se-
quencing of the other 5 internal genes 
(nonstructural, nucleoprotein, poly-
merase acidic, polymerase basic 1, 
and polymerase basic 2 proteins) was 
performed on 2 double-resistant strains 
isolated in April and on 3 isolated in 
June. Sequence comparison showed 
that 1 virus in April, in addition to ac-
quiring an M2 gene, acquired a non-
structural protein gene from an A/
Hong Kong/2652/2006-like clade 2C 
virus. All the viruses were susceptible 
to zanamivir and were not associated 
with unusual severity of disease.
Along with pandemic (H1N1) 
2009, seasonal inﬂ  uenza viruses con-
tinue to circulate in Hong Kong (3). 
An alarming proportion of the cir-
culating seasonal inﬂ  uenza  A  virus 
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Table. Prevalence of oseltamivir-resistant and amantadine- and oseltamivir-resistant influenza A virus (H1N1) detected in Hong Kong,
with clade designations, July 2008–June 2009 
Date detected
No. isolates 
tested
No. (%) isolates 
oseltamivir resistant
No. (%) isolates oseltamivir 
and amantadine resistant
Predominating influenza A virus (H1N1) clade, 
no. identified/total no. sequenced (%)
2008 Jul 462 78 (16.9) 4 (5.1) Clade 2C, 104/182 (57.1)
2008 Aug 313 45 (14.4) 1 (2.2) Clade 2C, 51/95 (53.7)
2008 Sep 61 21 (34.4) 1 (4.8) Clade 2B, 20/39 (51.3)
2008 Oct 19 13 (68.4) 0 Clade 2B, 13/16 (81.3)
2008 Nov 16 15 (93.8) 0 Clade 2B, 16/16 (100)
2008 Dec 45 44 (97.8) 0 Clade 2B, 41/41 (100)
2009 Jan 327 313 (95.7) 0 Clade 2B, 90/104 (86.5)
2009 Feb 769 755 (98.2) 0 Clade 2B, 138/153 (90.2)
2009 Mar 279 279 (100) 0 Clade 2B, 61/61 (100)
2009 Apr 63 63 (100) 2 (3.2) Clade 2B, 18/18 (100)
2009 May 22 22 (100) 2 (9.1) Clade 2B, 7/7 (100)
2009 Jun 77 77 (100) 46 (59.7) Clade 2B, 55/55 (100)